Commentary: The Benefit of Surgery for Stage III N2 Positive Non-Small Cell Lung Cancer is Independent of Where the Okies Go
Jeon et al. recently published a retrospective study of 385 patients who underwent lobectomy and lymph node dissection (35 thoracoscopy; 350 thoracotomy) after neoadjuvant concurrent chemoradiotherapy (CRT) between 2012 and 2017 for clinical N2 positive non-small cell lung cancer (cN2+NSCLC).1 Patients with residual nodal disease (55%) were offered adjuvant chemotherapy and/or radiation therapy. Propensity matched comparison between the 2 modalities, showed significantly lower major complication rate in the thoracoscopy group (9.7% vs 30.4%, P = 0.036).
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Abbas E. Abbas Tags: THORACIC – Commentary Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Heart | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Radiation Therapy | Study | Thoracotomy